



Preclinical Compound/Indication Category by Stage of Preclinical Development and Mechanism of Action (Non-COVID-19; N=56)*



- ▶ MOAs for Compound/Indications span the various stages of preclinical development.
- ▶ The majority of Approved or Investigational Antivirals for indication expansion are replication inhibitors.

*As of July 12, 2024


Preclinical Compound/Indication Category by Mechanism of Action and Stage of Preclinical Development (Non-COVID-19; N=56)*



- ▶ Compound/Indications span the various stages of preclinical development and MOAs.
- ▶ The MOA rank order is Replication, Entry, Protease, Assembly/Release.


*As of July 12, 2024

COVID-19 Compounds by Stage of Preclinical Development and Mechanism of Action (N=76)*



*As of July 12, 2024

COVID-19 Compounds by Mechanism of Action and Stage of Preclinical Development (N=76)*



*As of July 12, 2024



INTREPID ALLIANCE

INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

**Interested
in engaging
with us?**

We welcome all feedback through [our online portal](#). As with previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated quarterly.

For more information, contact nina@intrepidalliance.org.

 intrepidalliance.org

 linkedin.com/company/intrepid-alliance